Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the Pharmalot campus has quieted down. The shortest person has left for a new summer job overseeing even smaller people and the official mascots are enjoying snoozes under windows where cool breezes and a warm sunshine can be felt. As for us, we are quaffing cups of stimulation that sport a hint of Jack Daniel’s. As always, feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits. Hope you have a smashing day and please do keep in touch …

The House is touting passage of dozens of bills that could help combat the national opioid crisis, but a small handful of companies that have spent millions lobbying Congress could reap a windfall if any of the bills become law, Politico informs us. Among them is Alkermes (ALKS), which spent $1 million lobbying in part to support a bill to fund full-service centers where people can detox, receive medical care, and start treatment — a setup that could boost the fortunes of its best-selling product, anti-addiction treatment Vivitrol.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!